Quillien V, Ramee M P, Bansard J Y, Meritte H, Briens E, Logeais Y, Langanay T, Corbineau H, Dazord L
Centre de Lutte Contre le Cancer Eugène Marquis, Département de Biologie Clinique et Expérimentale, Rennes, France.
Anticancer Res. 1995 Nov-Dec;15(6B):2857-63.
A sensitive and relatively specific tumoral marker for lung epidermoid carcinomas could be used to identify patients likely to benefit from new therapeutic protocols. The cyfra 21-1 fragment of cytokeratin 19 has raised much hope in this regard amongst both technologists and clinicians. In a study of 195 subjects, we have shown by means of a serum assay that the usual cut-off value for this marker (3.3 ng/ml) can be lowered to 1.5 ng/ml without loss of specificity, and with an increase in sensitivity. There was a good correlation between serum marker level and tumor extension, but though cyfra 21-1 was not predictive of the suitability of a patient for surgery. A decrease of cyfra-21-1 was observed after complete resection of the tumor. There was no relation between serum assay results and immunohistochemical findings.
一种用于肺表皮样癌的敏感且相对特异的肿瘤标志物可用于识别可能从新治疗方案中获益的患者。细胞角蛋白19的细胞角蛋白片段CYFRA 21-1在技术人员和临床医生中都引发了很大的希望。在一项对195名受试者的研究中，我们通过血清检测表明，该标志物的常规临界值（3.3纳克/毫升）可降至1.5纳克/毫升，而不会丧失特异性，且敏感性增加。血清标志物水平与肿瘤扩展之间存在良好的相关性，但CYFRA 21-1不能预测患者是否适合手术。肿瘤完全切除后观察到CYFRA-21-1下降。血清检测结果与免疫组化结果之间没有关联。
